Commentary

Podcast

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Author(s):

Drs Lunning and Jacobson discuss the characteristics of follicular lymphoma that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies. Dr Lunning is an associate professor in the Division of Oncology & Hematology, associate vice chair of research in the Department of Internal Medicine, and assistant vice chancellor of clinical research at the University of Nebraska Medical Center in Omaha.

In this episode, Dr Lunning sits down with Caron A. Jacobson, MD, MMSc, to discuss challenges that can arise in the management of follicular lymphoma (FL). Dr Jacobson is the medical director of the Immune Effector Cell Therapy Program and a senior physician at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School, both in Boston, Massachusetts.

Drs Lunning and Jacobson discussed the characteristics of FL that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Daniel DeAngelo, MD, PhD
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.